NCT05451134

Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 300 (estimated)
• Sponsor: China National Center for Cardiovascular Diseases · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators will retrospectively analyze the clinical data of consecutive patients with pheochromocytomas and paragangliomas admitted between January 2018 and June 2020. The clinical characteristics of patients with and without dysglycemia will be compared, and whether surgery could improve the patients'dysglycemia will be also investigated.

Detailed description

This retrospective cohort study will include all consecutive adult patients who underwent surgery for PHEOs and catecholamine-secreting PGLs from January 2018 to June 2020. Patients with recurrent PPGLs, those who required steroids after adrenalectomy, and those with inadequate clinical records were excluded. The patients' electronic medical files were reviewed. Patients with dysglycemia included those with diabetes, or impaired fasting glucose, or impaired glucose tolerance. Clinical history data such as age, sex, body mass index (BMI), the presence of preoperative symptoms, biochemical test results, and tumor characteristics, such as tumor diameters and locations were extracted and analyzed.

Conditions

• Pheochromocytoma
• Paraganglioma

Interventions

Type	Name	Description
OTHER	Catecholamines	Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma

Timeline

• Start date: 2022-06-30
• Primary completion: 2022-07-20
• Completion: 2022-07-20
• First posted: 2022-07-11
• Last updated: 2022-07-12

Locations

1 site across 1 country: China